IMVT
IMVT
US45258J1025
Immunovant, Inc.
Loading chart...

Financials

Trends
* Timeframes marked with (Est.) are analyst estimates based on consensus data.
Details
Breakdown 2026 2025 Change %
Total Revenue -- --
--
Cost of Revenue -- --
--
Gross Profit -- --
--
532.902.000 438.152.000
21.6%
Operating Income -532.902.000 -438.152.000
21.6%
Pretax Income -505.391.000 -412.949.000
22.4%
Net Income Common Stockholders -505.606.000 -413.840.000
22.2%
-- --
--
-- --
--
ende